<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556411</url>
  </required_header>
  <id_info>
    <org_study_id>ADENOMYOSIS</org_study_id>
    <nct_id>NCT02556411</nct_id>
  </id_info>
  <brief_title>Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)</brief_title>
  <official_title>Comparison of E/P Therapy in Continuous Regimen Versus Combination of LNG-IUS Plus E/P</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cagliari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenomyosis is characterized by the appearance of endometrial cells in the muscular layer of&#xD;
      the uterus. It affects about 15-20% of the female population.&#xD;
&#xD;
      The symptoms of adenomyosis are heavy menstrual bleedings and painful menstruation&#xD;
      (dysmenorrhea) and in addition chronic pelvic pain. Regarding treatment&#xD;
      levonogestrel-releasing intrauterine system, Gonadotropin releasing hormone (GnRH)-analogues,&#xD;
      Danazol, uterine embolization and endometrial ablation have been tried. The aim of this study&#xD;
      is to compare the efficacy and usefulness of association of oral contraceptive pill and&#xD;
      LNG-IUS or LNG-IUS alone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pelvic pain as measured by visual analogue scale</measure>
    <time_frame>Change from baseline pelvic pain at 45 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Pelvic pain as measured by visual analogue scale</measure>
    <time_frame>Change from baseline pelvic pain at 90 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pelvic pain as measured by visual analogue scale</measure>
    <time_frame>Change from baseline pelvic pain at 180 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pelvic pain as measured by visual analogue scale</measure>
    <time_frame>Change from baseline pelvic pain at 365 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sexual life</measure>
    <time_frame>Cases were administered and fulfilled the questionnaires at the moment of diagnosis of adenomyosis up to 4weeks; Change from baseline were evaluated 45 days after begin of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Adenomyosis</condition>
  <condition>Chronic Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>LNG-IUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LNG-IUS 13,5 mg di Levonorgestrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combined oral contraceptive plus LNG-IUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG-IUS 13,5 mg Levonorgestrel</intervention_name>
    <description>LNG-IUS</description>
    <arm_group_label>LNG-IUS</arm_group_label>
    <arm_group_label>combined oral contraceptive plus LNG-IUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg</intervention_name>
    <description>Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime</description>
    <arm_group_label>combined oral contraceptive plus LNG-IUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women affected by adenomyosis with pelvic pain &gt; 4;&#xD;
&#xD;
          -  Negative Pap Smear test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or research of pregnancy&#xD;
&#xD;
          -  Refusal or inability to sign informed consent&#xD;
&#xD;
          -  Severe underlying comorbidities (hepatic, oncological)&#xD;
&#xD;
          -  Pelvic inflammatory disease&#xD;
&#xD;
          -  Other cervical or uterine pathologies&#xD;
&#xD;
          -  Deep venous thromboembolism&#xD;
&#xD;
          -  Hormonal therapy contraindications&#xD;
&#xD;
          -  Smoke&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Stefano Angioni</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

